XML 96 R80.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Collaboration and Licensing Revenue - Additional Information (Details) | 1 Months Ended | 5 Months Ended | 12 Months Ended
--- | --- | --- | ---
Sep. 30, 2016 USD ($) | Jun. 30, 2016 USD ($) shares | Mar. 31, 2016 USD ($) | Dec. 31, 2015 USD ($) shares | Sep. 30, 2015 USD ($) | Jun. 30, 2015 USD ($) | May 31, 2015 USD ($) target | Dec. 31, 2014 USD ($) | Mar. 31, 2014 USD ($) | Jan. 31, 2014 USD ($) shares | Dec. 31, 2013 shares | Sep. 30, 2013 USD ($) shares | Jun. 30, 2013 USD ($) shares | Mar. 31, 2013 USD ($) | Feb. 28, 2013 | Oct. 31, 2012 USD ($) shares | Jun. 30, 2012 USD ($) shares | Jan. 31, 2011 USD ($) shares | May 31, 2016 | Dec. 31, 2016 USD ($) | Dec. 31, 2015 USD ($) | Dec. 31, 2014 USD ($)
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 109,871,000 | $ 87,821,000 | $ 45,212,000
Deferred revenue |  |  |  | $ 197,729,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 310,142,000 | 197,729,000 |
Trade, net |  |  |  | 25,101,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 21,637,000 | 25,101,000 |
Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 34,433,000 | 32,513,000 | 9,625,000
Deferred revenue |  |  |  | 181,331,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 297,867,000 | 181,331,000 |
Prepaid research and development services |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  | 10,938,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,015,000 | 10,938,000 |
ZIOPHARM ECC 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7.495% |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |
ZIOPHARM ECC 1 | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,636,926 |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 17,457,000 |  |  |  |
ZIOPHARM ECC 1 | Milestone One | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,636,926 |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 18,330,000 |  |  |  |  |  |
ZIOPHARM ECC 1 Separate Unit Of Accounting | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,115,000 |  |  |  |
ZIOPHARM ECC 1 Unit of Accounting 1 | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 16,342,000 |  |  |  |
ZIOPHARM Oncology, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 33,836,000 | 19,306,000 | 14,621,000
Royalty rate as a percentage of net profit |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |
ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11,529,000 | 2,855,000 | 2,577,000
Deferred revenue |  |  |  | 30,338,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 138,809,000 | 30,338,000 |
ZIOPHARM Oncology, Inc. | Other Contractual Payments | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  | $ 120,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, number of preferred shares (in shares) | shares |  | 100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ares Trading S.A. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,192,000 | 4,728,000 |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trade, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,750,000 |  |
Collaborative agreement, additional target fee |  |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ares Trading S.A. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,389,000 | 3,933,000 |
Deferred revenue |  |  |  | $ 53,567,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 47,178,000 | 53,567,000 |
Ares Trading S.A. | Prepaid research and development services |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration receivable, minimum targets required | target |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration receivable, collection period |  |  |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ares Trading S.A. | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  | $ 115,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ZIOPHARM ECC 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ZIOPHARM ECC 2 | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Oragenics ECC 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.00% |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |
Royalty rate as a percentage of net profit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25.00% |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.50% |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.00% |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.50% |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3.00% |  |  |  |  |
Oragenics ECC 1 | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,392,425 |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,588,000 |  |  |  |  |
Oragenics ECC 2 | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  | 1,348,000 |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  |  |  |  |  | $ 3,503,000 |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value of convertible promissory note |  |  |  |  |  |  |  |  |  |  |  | $ 1,956,000 |  |  |  |  |  |  |  |  |  |
Conversion of promissory note into common stock (in shares) | shares |  |  |  |  |  |  |  |  |  |  | 698,241 |  |  |  |  |  |  |  |  |  |  |
Oragenics ECC 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Oragenics ECC 3 | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value of convertible promissory note |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Conversion of promissory note into common stock (in shares) | shares |  |  |  | 3,381,004 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fibrocell ECC 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |
Royalty rate as a percentage of net sales, tier 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7.00% |  |  |  |  |  |
Level of net sales at which royalty rate changes to tier 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 25,000,000 |  |  |  |  |  |
Royalty rate as a percentage of net sales, tier 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 14.00% |  |  |  |  |  |
Royalty rate of savings from improvement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 33.00% |  |  |  |  |  |
Fibrocell ECC 1 | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,317,520 |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,576,000 |  |  |  |  |  |
Fibrocell ECC 1 | Supplemental Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received (in shares) | shares |  |  |  |  |  |  |  |  |  | 1,024,590 |  |  | 1,243,781 |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  |  |  | $ 5,225,000 |  |  | $ 7,612,000 |  |  |  |  |  |  |  |  |
Fibrocell ECC 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payments required upon successful achievement, first product |  |  |  | $ 30,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payments required upon successful achievement, per each additional product |  |  |  | 30,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payments required for certain sales milestones, per product |  |  |  | 22,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fibrocell ECC 2 | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  | 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Genopaver, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,117,000 | 3,829,000 | 1,783,000
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |
Genopaver, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 273,000 | 273,000 | 273,000
Deferred revenue |  |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,977,000 | 2,250,000 |
Genopaver, LLC | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |
AquaBounty Technologies, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate as a percentage of gross profit |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16.66% |  |  |  |  |  |  |
S & I Ophthalmic, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,141,000 | 4,115,000 | 2,832,000
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |
S & I Ophthalmic, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0
OvaXon, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,934,000 | 2,540,000 | 2,799,000
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |
OvaXon, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0
Intrexon Energy Partners, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 17,552,000 | 13,447,000 | 6,102,000
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |
Intrexon Energy Partners, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,500,000 | 2,500,000 | $ 1,875,000
Deferred revenue |  |  |  | 20,625,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18,125,000 | 20,625,000 |
Intrexon Energy Partners, LLC | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  |  | $ 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Persea Bio, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,278,000 | 1,241,000 |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |
Persea Bio, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 500,000 | 500,000 |
Deferred revenue |  |  |  | 4,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,000,000 | 4,500,000 |
Persea Bio, LLC | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Thrive Agrobiotics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,714,000 | 266,000 |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Thrive Agrobiotics, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 185,000 | 46,000 |
Deferred revenue |  |  |  | $ 1,621,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,436,000 | 1,621,000 |
Thrive Agrobiotics, Inc. | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  | $ 1,667,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intrexon Energy Partners II, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,169,000 | 167,000 |
Required notice period for voluntary termination of collaborative agreement |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intrexon Energy Partners II, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,000,000 | 167,000 |
Deferred revenue |  |  |  | $ 17,833,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,833,000 | 17,833,000 |
Intrexon Energy Partners II, LLC | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  | 18,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exotech Bio, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 792,000 |  |
Required notice period for voluntary termination of collaborative agreement |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exotech Bio, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 417,000 |  |
Deferred revenue |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,583,000 | 0 |
Exotech Bio, Inc. | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Relieve Genetics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,239,000 |  |
Required notice period for voluntary termination of collaborative agreement |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Relieve Genetics, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 361,000 |  |
Deferred revenue |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,972,000 | 0 |
Relieve Genetics, Inc. | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  | $ 4,333,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intrexon T1D Partners, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,908,000 |  |
Required notice period for voluntary termination of collaborative agreement |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intrexon T1D Partners, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 821,000 |  |
Deferred revenue |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,653,000 | 0 |
Intrexon T1D Partners, LLC | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AD Skincare, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 695,000 |  |
Required notice period for voluntary termination of collaborative agreement |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AD Skincare, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 241,000 |  |
Deferred revenue |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,092,000 | 0 |
AD Skincare, Inc. | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  | $ 4,333,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Genten Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 386,000 |  |
Required notice period for voluntary termination of collaborative agreement | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Genten Therapeutics, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 122,000 |  |
Deferred revenue |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,176,000 | 0 |
Genten Therapeutics, Inc. | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, cash | $ 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
CRS Bio, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 148,000 |  |
Required notice period for voluntary termination of collaborative agreement | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
CRS Bio, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 57,000 |  |
Deferred revenue |  |  |  | $ 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,949,000 | $ 0 |
CRS Bio, Inc. | Upfront | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value | $ 2,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ZIOPHARM Oncology, Inc. | Ares Trading S.A. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, percent of collaboration payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |
Payments to related parties |  |  |  |  |  |  | 57,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum | Ares Trading S.A. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments required upon successful achievement, per product |  |  |  |  |  |  | 413,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments required upon successful achievement, one-time |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum | Oragenics ECC 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments required upon successful achievement, per product |  |  |  |  |  | 22,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments required upon successful achievement, one-time |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum | Thrive Agrobiotics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments required upon successful achievement, per product |  |  |  |  | $ 5,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum | Exotech Bio, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments required upon successful achievement, per product |  |  | 52,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum | Relieve Genetics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments required upon successful achievement, per product |  |  | $ 52,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum | AD Skincare, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments required upon successful achievement, per product |  | 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments required upon successful achievement, one-time |  | $ 17,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum | Genten Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments required upon successful achievement, per product | 82,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum | CRS Bio, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments required upon successful achievement, per product | $ 75,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 + Details
Name: | us-gaap_DebtConversionConvertedInstrumentSharesIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Notice period required for voluntary termination of collaboration. + References No definition available. + Details
Name: | xon_CollaborationAgreementTerminationNoticePeriod
Namespace Prefix: | xon_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreements [Line Items] + References No definition available. + Details
Name: | xon_CollaborationAgreementsLineItems
Namespace Prefix: | xon_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue from contractual agreements with collaborators whereby the collaborators obtain exclusive access to the entity's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use as well as revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Includes revenue recognized from upfront payments received upon consummation of the agreement, reimbursements for costs incurred by the entity for research and development efforts, and milestone payments received upon achievement of specified development, regulatory and commercial activities as defined in the collaboration and licensing agreements. + References No definition available. + Details
Name: | xon_CollaborationAndLicensingRevenue
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percent of collaboration payments received pursuant to a collaboration agreement for upfront fees, milestones and royalties which will be paid to another party. + References No definition available. + Details
Name: | xon_CollaborationArrangementPercentOfCollaborationPayments
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of consideration to be received from the licensee if the licensee selects an additional target. + References No definition available. + Details
Name: | xon_CollaborativeAgreementAdditionalTargetFee
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingShares
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 5. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFive
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 4. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFour
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 3. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesThree
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 2. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesTwo
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The period over which the consideration is owed to the entity under a collaboration agreement. + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivableCollectionPeriod
Namespace Prefix: | xon_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of targets selected by a collaborator under a collaboration agreement which result in consideration owed to the entity. + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired
Namespace Prefix: | xon_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of cash received by the entity as consideration for collaboration + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedCash
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of preferred stock of a collaborator received by the entity as consideration. + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedPreferredShares
Namespace Prefix: | xon_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of common stock of a collaborator received by the entity as consideration + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedShares
Namespace Prefix: | xon_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of consideration received by the entity for collaboration + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedValue
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of promissory note received as consideration of collaboration agreement which can be settled in cash or common stock. + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Level of net sales, as defined in the collaboration agreement, at which the royalty rate changes to tier 2. + References No definition available. + Details
Name: | xon_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 1. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 2. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of gross profit, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltyRateAsPercentageOfGrossProfit
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of net profit, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltyRateAsPercentageOfNetProfit
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of cost of goods sold, as defined in the collaboration agreement, savings generated by production improvements used to calculate royalty payments to which the entity is entitled. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltyRateAsPercentageOfSavingsFromImprovement
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of potential future milestone payments to be received under agreement for certain sales milestones per product, maximum + References No definition available. + Details
Name: | xon_MaximumMilestonePaymentsRequiredForCertainSalesMilestonesPerProduct
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of potential future milestone payments to be received under agreement for first product, maximum + References No definition available. + Details
Name: | xon_MaximumMilestonePaymentsRequiredUponSuccessfulAchievementFirstProduct
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of potential future milestone payments to be received under agreement per each additional product, maximum + References No definition available. + Details
Name: | xon_MaximumMilestonePaymentsRequiredUponSuccessfulAchievementPerEachAdditionalProduct
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of potential future milestone payments to be received under agreement one-time + References No definition available. + Details
Name: | xon_MilestonePaymentsRequiredUponSuccessfulAchievementOneTime
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of potential future milestone payments to be received under agreement per product + References No definition available. + Details
Name: | xon_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash outflows for payments made to related parties. + References No definition available. + Details
Name: | xon_PaymentsToRelatedParties
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xon_UpfrontAndMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xon_PrepaidResearchAndDevelopmentServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ZiopharmOncologyEccMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xon_UpfrontMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xon_MilestoneOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ZiopharmOncologyEccSeparateUnitOfAccountingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ZiopharmOncologyEccUnitOfAccountingOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xon_OtherContractualPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_AresTradingS.A.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ZiopharmOncologyEccTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OragenicsEccMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OragenicsSecondEccMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OragenicsThirdEccMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_FibrocellScienceEccMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xon_SupplementalUpfrontMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_FibrocellScienceECC2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_GenopaverLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_AquaBountyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_SIOphthalmicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OvaXonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonEnergyPartnersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_PerseaBioLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ThriveAgrobioticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonEnergyPartnersIILLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ExotechBioInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_RelieveGeneticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonT1DPartnersLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ADSkincareInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_GentenTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_CRSBioInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |